文献速递血栓与止血

静脉血栓栓塞症患者天然抗凝物质缺陷的基因型与实验室表型相关性

Genotype vs laboratory phenotype correlation of defects in natural anticoagulants in patients with venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2025-05-26

研究比较317例静脉血栓栓塞症患者的多基因panel结果与蛋白C、蛋白S、抗凝血酶血浆活性或抗原水平,发现110例携带PROC、PROS1或SERPINC1变异且61%为(可能)致病性变异,33%存在寡基因遗传;部分变异不伴血浆活性降低,而无变异患者中14%、20%、5%分别有蛋白C、蛋白S、抗凝血酶水平降低。

要点

  • 多基因panel在110/317例VTE患者中检出PROC、PROS1或SERPINC1变异,61%为(可能)致病性变异。
  • 33%患者存在寡基因遗传,并非所有变异均伴血浆活性降低。
  • 无基因变异VTE患者中14%、20%、5%分别有蛋白C、蛋白S、抗凝血酶水平降低。

核心结论

  • 基于血浆的易栓症筛查可导致潜在的诊断误分类,多基因panel检测更敏感但仍会检出意义未明变异。
  • 需要额外研究来阐明panel检测在遗传性VTE中的作用及寡基因遗传的影响。

研究设计与样本

  • 研究将基因panel检测结果与标准易栓症实验室检测数据(包括蛋白C、蛋白S和抗凝血酶血浆活性或抗原水平)进行比较。
  • 研究纳入317例静脉血栓栓塞症患者,并额外进行基于凝块的功能性蛋白C和蛋白S检测及用于检测抗凝血酶分子蛋白质形式的质谱分析。

主要发现

  • 在317例VTE患者中,110例检出PROC、PROS1或SERPINC1变异,其中61%为(可能)致病性变异。
  • 所有患者中33%存在寡基因遗传。
  • 相关性研究显示并非所有变异均与血浆活性水平降低相关。
  • 无基因变异的VTE患者中,分别有14%、20%和5%存在蛋白C、蛋白S和抗凝血酶水平降低。
  • 额外的基于凝块的检测可诊断额外患者,但并非全部;基于质谱的抗凝血酶检测能够检测出血浆中抗凝血酶活性水平正常的SERPINC1错义变异。

局限性

  • 需要额外研究来阐明panel检测在遗传性VTE中的作用及寡基因遗传的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasma-based assays or multigene panel testing can be used for the diagnosis of inherited venous thromboembolism (VTE). Our recent multigene panel data showed strictly concordant results between genetic and phenotypic laboratory testing in only half of the patients. OBJECTIVES: We aimed to evaluate in detail the correlation between genotype and laboratory phenotype for defects in natural anticoagulants. METHODS: Gene panel test results were compared with standard thrombophilia laboratory assay data, including protein C, protein S, and antithrombin plasma activity or antigen levels. We performed additional functional protein C and protein S clot-based assays and mass spectrometry for the detection of antithrombin molecular proteoforms. RESULTS: We detected PROC, PROS1, or SERPINC1 variants in 110 of 317 patients with VTE of which 61% were (likely)pathogenic variants. Oligogenic inheritance was present in 33% of all patients. Correlation studies showed that not all variants were associated with reduced plasma activity levels, while 14%, 20%, and 5% of our patients with VTE but without a genetic variant had reduced levels for protein C, protein S, and antithrombin, respectively. Additional clot-based assays could diagnose additional patients but not all. Mass spectrometry-based antithrombin assay was able to detect SERPINC1 missense variants in plasmas that were associated with normal antithrombin activity levels. CONCLUSIONS: Thrombophilia screening using plasma-based assays can lead to potential diagnostic misclassification. In contrast, multigene panel testing is more sensitive but still associated with the detection of variants of uncertain significance. Additional studies are required to clarify the role of panel testing for inherited VTE and the impact of oligogenic inheritance.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Van Laer C, Vanrenterghem M, Jacquemin M, et al. Genotype vs laboratory phenotype correlation of defects in natural anticoagulants in patients with venous thromboembolism. J Thromb Haemost. 2025. PMID: 40436275. doi:10.1016/j.jtha.2025.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。